Febrile urinary-tract infection due to extended-spectrum beta-lactamase–producing Enterobacteriaceae in children: A French prospective multicenter study
Open Access
- 25 January 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (1) , e0190910
Abstract
To assess the management of febrile urinary-tract infection (FUTIs) due to extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL-E) in children, the Pediatric Infectious Diseases Group of the French Pediatric Society set up an active surveillance network in pediatric centers across France in 2014. We prospectively analysed data from 2014 to 2016 for all children < 18 years old who received antibiotic treatment for FUTI due to ESBL-E in 24 pediatric centers. Baseline demographic, clinical features, microbiological data and antimicrobials prescribed were collected. 301 children were enrolled in this study. The median age was 1 year (IQR 0.02–17.9) and 44.5% were male. These infections occurred in children with history of UTIs (27.3%) and urinary malformations (32.6%). Recent antibiotic use was the main associated factor for FUTIs due to ESBL-E, followed by a previous hospitalization and travel history. Before drug susceptibility testing (DST), third-generation cephalosporins (3GC) PO/IV were the most-prescribed antibiotics (75.5%). Only 13% and 24% of children received amikacine alone for empirical or definitive therapy, respectively, whereas 88.7% of children had isolates susceptible to amikacin. In all, 23.2% of children received carbapenems in empirical and/or definitive therapy. Cotrimoxazole (24.5%), ciprofloxacin (15.6%) and non-orthodox clavulanate–cefixime combination (31.3%) were the most frequently prescribed oral options after obtaining the DST. The time to apyrexia and length of hospital stay did not differ with or without effective empirical therapy. We believe that amikacin should increasingly take on a key role in the choice of definitive therapy of FUTI due to ESBL-E in children by avoiding the use of carbapenems.Keywords
This publication has 46 references indexed in Scilit:
- New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?Clinical Microbiology and Infection, 2017
- Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysisJournal of Infection, 2016
- Epidemiology and characteristics of urinary tract infections in children and adolescentsFrontiers in Cellular and Infection Microbiology, 2015
- Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15Journal of Antimicrobial Chemotherapy, 2015
- Treatment of Resistant Bacterial Infections in Children: Thinking Inside and Outside the Box2012
- Febrile Urinary Tract Infections in ChildrenNew England Journal of Medicine, 2011
- Optimizing Aminoglycoside UseCritical Care Clinics, 2011
- Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guideClinical Microbiology and Infection, 2008
- Diagnosis and management of urinary tract infection in children: summary of NICE guidanceBMJ, 2007
- Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up.BMJ, 1989